Suppliers in Seattle, WA
116 Medicare Suppliers found. Showing 61 - 80
 Bartell Drug Company Drug Store # 8 Pharmacy Location: 9600 15th Ave Sw, Seattle, Washington 98106 Phone: (206) 763-2728 |
Bartell Drug Company Store # 14 Pharmacy Location: 1820 N 45th St, Seattle, Washington 98103 Phone: (206) 632-3314 |
Bartell Drug Company Store # 16 Pharmacy Location: 4706 42nd Ave Sw, Seattle, Washington 98116 Phone: (206) 932-8045 |
Bartell Drug Company Store # 31 Pharmacy Location: 2700 Ne University Village St, Seattle, Washington 98105 Phone: (206) 525-0705 |
Bartell Drug Company Store # 37 Medicare Supplier Location: 1404 3rd Ave, Seattle, Washington 98101 Phone: (206) 624-3508 |
Bartell Drug Company Store # 9 Pharmacy Location: 120 N 85th St, Seattle, Washington 98103 Phone: (206) 784-7601 |
Bartell Drug Company Store #1 Pharmacy Location: 1628 5th Ave, Seattle, Washington 98101 Phone: (206) 622-0582 |
Bartell Drug Company Store# 10 Pharmacy Location: 1101 Madison St, Seattle, Washington 98104 Phone: (206) 340-1171 |
|
Bartell Drugs # 67 Pharmacy Location: 1929 Queen Anne Ave N, Seattle, Washington 98109 Phone: (206) 285-1737 |
|
|
|
|
|
Bartell Drugs #63 Community/Retail Pharmacy Location: 2345 Rainier Ave S, Seattle, Washington 98144 Phone: (206) 325-5725 |
|
|
|
|
News Archive
Immunotherapies may increase overall survival in patients with melanoma brain metastases
Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
Single gene variation may influence obesity in children, adults
A single variation in the gene for brain-derived neurotropic factor (BDNF) may influence obesity in children and adults, according to a new study funded by the National Institutes of Health.
TearScience completes $44.5 million Series C funding
TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.
MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference
AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.
Current situation on SARS outbreaks in China
On 22 April, the World Health Organization (WHO) reported a case of SARS in China, who was a 20-year-old nurse from Beijing. She was admitted to Jiangong Hospital on 7 April, transferred to Remin Hospital (Beijing People's Hospital) on 14 April and then to Ditang Hospital (in Beijing) on 19 April.
› Verified 8 days ago